Pfizer agreed to pay $23.85 million to resolve alleged violations of the False Claims Act. The government accused Pfizer of using a foundation as a conduit to pay the copay obligations of Medicare patients taking the Pfizer drugs Sutent, Inlyta, and Tikosyn. Under the Anti-Kickback Statute, pharmaceutical companies are prohibited from offering, directly or indirectly, any remuneration—which includes the payment of copays—to induce Medicare patients to purchase the companies’ products. Pfizer also entered into a corporate integrity agreement with the Department of Health and Human Services Office of Inspector General requiring Pfizer to implement measures designed to ensure that arrangements and interactions with third-party patient assistance programs are compliant with the law.